Hepatitis B Community
Reduction of HBsAg & cccDNA by NUCs
About This Community:

This forum is an un-mediated, patient-to-patient forum for questions and support regarding Hepatitis B. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hepatitis B, Research Updates, Treatment, Success Stories, Support, Symptoms.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Reduction of HBsAg & cccDNA by NUCs

Clin Gastroenterol Hepatol. 2013 Jan 31. pii: S1542-3565(13)00169-9. doi: 10.1016/j.cgh.2013.01.026. [Epub ahead of print]
Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency.
Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF.

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China; State Key Laboratory for Liver Research, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
Abstract
BACKGROUND & AIMS:

Few studies have investigated the effects of different nucleos(t)ide analogues against hepatitis B virus (HBV) on level of covalently closed circular (ccc)DNA and hepatitis B surface antigen (HBsAg) in patients. We measured the magnitude of reduction of cccDNA and HBsAg by nucleos(t)ide analogue therapy and assessed the correlation between their reductions.
METHODS:

We recruited 124 patients who were treated with one of the 5 nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine, or clevudine). All patients had undergone liver biopsy when treatment began (baseline) and 1 year later. cccDNA and HBsAg were measured by real-time PCR and the Elecsys II HBsAg Assay, respectively.
RESULTS:

After 1 year of treatment, HBV in 7 patients had become resistant to the nucleos(t)ide analogue. The remaining 117 patients had an average reduction of approximately 0.2 log10 IU/mL in HBsAg, 5 log10 IU/mL in serum level of HBV DNA, 2 log10 copies/cell in intrahepatic total HBV DNA, and 1 log10 copies/cell in cccDNA. Although 88/117 patients (75%) had undetectable serum levels of HBV DNA (<12 IU/mL), all had detectable levels of HBsAg, and only 5 (4%) had undetectable levels of cccDNA. Upon treatment with nucleos(t)ide analogues, patients with greater reductions in levels of cccDNA had greater reductions in HBsAg, but these reductions did not reach statistical significant correlations .
CONCLUSIONS:

Although nucleos(t)ide analogues potently reduced serum levels of HBV DNA, the reduction of HBsAg and cccDNA was small. In short-term therapy, the magnitude of HBsAg reduction does not correlate with that of cccDNA reduction.
Tags: hbsag, cccDNA, NUCs
8 Comments Post a Comment
Blank
Avatar_m_tn
Is there any detailed info about the 7 with resistance ? How does it divide upon particular drugs?
Blank
Avatar_m_tn
You will have to read the full paper which requires a fee or membership.
Blank
Avatar_m_tn

these studies are still missing the most potent antiviral tenofovir or the combo tenofovir plus entecavir or tenofovir plus telbivudine, although there is probably little difference we do need to know the effect on cccdna of the most potent combos
i hope sooner or later we will have these resports and also the reports of cccdna on intfplus tdf
Blank
Avatar_m_tn
The full paper may discuss the differences amongst the antivirals. I am surprised that there are drops in HBsAg and cccDNA, however small. Also remember that this is only a one year study. It will be nice to monitor patients over a longer period of time and offer an explanation for the decrease in cccDNA - is it due to reduction in the refurbishing of the cccDNA pool by re-infection and by recycling, followed by a reduction in the cccDNA pool through loss during cell division? Or is it due loss of infected cells by the actions of temporarily rekindled CD8+ T cells?
Blank
Avatar_m_tn
i missed the time was so little, 1 year study is absolutely useless for nucs we need a study on 5 years minimum

i think reinfection is the point myrcludex will show if persistance is due to reinfection

Blank
Avatar_m_tn
What are the tests/diagnosis that indicate presence of cccDNA?
Blank
Avatar_m_tn
From a piece of the liver through biopsy. They must have developed assays that would allow them to measure intrahepative (inside the liver) HbsAg, hbvdna and cccDNA from the liver tissue.
Blank
Avatar_m_tn
Hopefully with Myrcludex-B or the discovery of the HBV receptor will lead to therapy that will block or slow down the reinfection cycle.
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
Avatar_m_tn
Blank
stef2011
Italy
Avatar_m_tn
Blank
veteranB
CA
9624973_tn?1413019730
Blank
melcul
United Kingdom
Avatar_m_tn
Blank
StephenCastlecrag
Australia
Avatar_m_tn
Blank
luckyman316
Avatar_m_tn
Blank
SafiSifa
Izmir, Turkey